You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

untreated metastatic squamous neck cancer with occult primary

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell

Active, not recruiting
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • +29 more
  • Cytology specimen
  • Laboratory biomarker analysis
  • Philadelphia, Pennsylvania
    Thomas Jefferson University
Aug 31, 2021

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Head Neck Cancer Metastatic Trial in Baltimore (Nivolumab 480mg and

Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
  • Nivolumab 480mg and surgical resection
  • Baltimore, Maryland
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Feb 25, 2022

Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma Trial in Portland (GB1211, Pembrolizumab, Placebo)

Not yet recruiting
  • Metastatic Melanoma
  • Head and Neck Squamous Cell Carcinoma
  • Portland, Oregon
    Providence Portland Medical Center
Jun 19, 2023

Prognostic Immune Biomarkers in HNSCC

Completed
  • Head and Neck Cancer
  • Squamous Cell Carcinoma
  • Tumour immunoprofile evaluation
  • Ostrava, Moravian-Silesian Region, Czechia
    University Hospital Ostrava
Jul 3, 2023

Head and Neck Squamous Cell Carcinoma Trial in Shanghai (BL-B01D1, SI-B003)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 17, 2023

Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • +4 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 19, 2023

Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
  • Panitumumab
  • +4 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Feb 16, 2023

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer Trial (Tislelizumab, BGB-A425, LBL-007)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Head and Neck Cancer
  • (no location specified)
Jun 9, 2023

Cancer of Unknown Primary Site, Unknown Primary Cancer, Unknown Primary, Squamous Cell Carcinoma Trial in Copenhagen, Århus

Recruiting
  • Cancer of Unknown Primary Site
  • +2 more
  • Transoral Ultrasound
  • Copenhagen, Denmark
  • +1 more
May 2, 2023

Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)

Not yet recruiting
  • Sinonasal Cancer
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 5, 2023

HLA-DR in Cell Cultures Isolated From Primary Squamous Cell

Active, not recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • Cancer
  • cell culture
  • Roma, Lazio, Italy
    Fondazione Policlinico Universitario Gemelli, Irccs
Sep 11, 2023

Recurrent Head Neck Cancer, Head Neck Cancer, Head and Neck Tumors Trial in Cincinnati (Durvalumab, Cetuximab)

Active, not recruiting
  • Recurrent Head and Neck Cancer
  • +3 more
  • Cincinnati, Ohio
    UC Health
Oct 3, 2022

Head Neck, Squamous Cell Carcinoma of Head and Neck Trial in Houston (Pembrolizumab, Magrolimab, cetuximab)

Not yet recruiting
  • Head Neck
  • Squamous Cell Carcinoma of Head and Neck
  • Houston, Texas
    M D Anderson Cancer Center
Sep 14, 2023

Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous

Active, not recruiting
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • +3 more
  • 200 mg Pembrolizumab
  • +2 more
  • Miami, Florida
  • +6 more
Jan 9, 2023

Head Neck Cancer, Squamous Cell Carcinoma of the Head and Neck Trial in La Jolla (Ibrutinib 560mg PO daily (Imbruvica),

Active, not recruiting
  • Head and Neck Cancer
  • Squamous Cell Carcinoma of the Head and Neck
  • Ibrutinib 560mg PO daily (Imbruvica)
  • +2 more
  • La Jolla, California
    UCSD Moores Cancer Center
Jan 11, 2023

Head and Neck Squamous Cell Cancer Trial (pembrolizumab, methotrexate, docetaxel)

Completed
Has Results
  • Head and Neck Squamous Cell Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 24, 2022

Recurrent Head and Neck Squamous Cell Carcinoma Trial in Atlanta, Cleveland, Milwaukee (IMRT, Nivolumab)

Active, not recruiting
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • IMRT
  • Nivolumab
  • Atlanta, Georgia
  • +3 more
Jan 10, 2023

Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint

Not yet recruiting
  • Recurrent Head and Neck Cancer
  • +5 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 30, 2023

Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity

Active, not recruiting
Has Results
  • Squamous Cell Carcinoma of the Oropharynx
  • +7 more
  • Tampa, Florida
  • +2 more
Dec 30, 2022

Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma Trial in China (TQB2618 injection,

Not yet recruiting
  • Recurrent Squamous Cell Carcinoma of the Head and Neck
  • Metastatic Squamous Cell Carcinoma
  • TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin
  • Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin
  • Lanzhou, Gansu, China
  • +11 more
Mar 23, 2023

Head Neck Cancer Trial in Charleston (Pembrolizumab, Clopidogrel, acetylsalicylic acid)

Recruiting
  • Head and Neck Cancer
  • Charleston, South Carolina
    Medical University of South Carolina
Dec 22, 2022

Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx

Active, not recruiting
Has Results
  • Head and Neck Squamous Cell Carcinoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 11, 2022

Head Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck Trial

Not yet recruiting
  • Head and Neck Cancer
  • +4 more
  • Ozuriftamab Vedotin
  • PD-1 inhibitor
  • (no location specified)
Jul 28, 2022

Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin Trial in Australia, United States (TH-4000)

Terminated
  • Metastatic Head-and-neck Squamous-cell Carcinoma
  • TH-4000 (Tarloxotinib)
  • Los Angeles, California
  • +9 more
Jan 9, 2023

Head Neck Cancer, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma Trial in Winston-Salem (Pembrolizumab,

Recruiting
  • Head Neck Cancer
  • +5 more
  • Winston-Salem, North Carolina
    Wake Forest Baptist Health Sciences
Aug 8, 2022